Connect Biopharma vs Dianthus Therapeutics
CNTB and DNTH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNTB and DNTH compare
Dianthus Therapeutics scores higher on the StockData Score (7 against 6 for Connect Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNTB | DNTH |
|---|---|---|
| Size and price | ||
| Market cap | – | $5.0B |
| Share price | $0.689 | $89.30 |
| Change, 1 year | −54.7% | 144% |
| Change, 5 years | −86.5% | −16.6% |
| Beta (5Y) | 0.53 | 1.44 |
| Employees | – | 92 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 4.0× |
| Growth | ||
| Revenue growth (TTM) | 50.3% | – |
| Profitability | ||
| Operating margin | −2384% | – |
| Net margin | −2336% | – |
| FCF margin | −2053% | – |
| Return on equity | −141% | −22.6% (better) |
| Return on invested capital | – | −22.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.37 | 30.02 (better) |
| Altman Z-score | – | 85.71 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −0.01% |
| Shareholder yield | – | −0.01% |
| Ownership | ||
| Held by institutions | 22.1% | 118% |
| Held by insiders | 31.6% | 9.1% |
| Insider net buying, 12 months | $4.4M (better) | −$63.8M |
| Short interest, % of float | – | 18.2% |
Go deeper
- CNTB stock overview
- CNTB income statement
- CNTB valuation and score
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.